High-Risk Clinical Trials

1 recruiting

High-Risk Trials at a Glance

54 actively recruiting trials for high-risk are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Not Applicable with 18 trials, with the heaviest enrollment activity in Shanghai, New York, and Guangzhou. Lead sponsors running high-risk studies include Fudan University, Shanghai Hengrui Pharmaceutical Co., Ltd., and Amsterdam UMC, location VUmc.

Browse high-risk trials by phase

Treatments under study

About High-Risk Clinical Trials

Looking for clinical trials for High-Risk? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High-Risk trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High-Risk clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 54 trials

Recruiting
Not Applicable

ELEVATE High-Risk PCI Pivotal Study

High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.290 enrolled29 locationsNCT07001332
Recruiting
Not Applicable

Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention

ECMOHigh-risk PCI
Beijing Anzhen Hospital176 enrolled1 locationNCT06274411
Recruiting
Phase 2

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

High-Risk Oral Precancerous Disease
Glenn J. Hanna25 enrolled2 locationsNCT06623110
Recruiting

Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer

Treatment ResponseHigh-risk Prostate CancerPSMA PET+1 more
Xijing Hospital110 enrolled9 locationsNCT07553780
Recruiting

Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform

High-risk Cardiac Patients
Idoven 1903 S.L.200,000 enrolled4 locationsNCT07333547
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Prostate CancerLocalized Prostate CarcinomaHigh-risk Prostate Cancer+2 more
Thomas Hope45 enrolled1 locationNCT07054346
Recruiting
Phase 2

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124
Recruiting
Phase 2

ASCT With TEAM Conditioning for Lymphoma With High Risk of CNS Relapse

Lymphoma Patients With High-risk of Central Nervous System Relapse
Second Affiliated Hospital, School of Medicine, Zhejiang University45 enrolled1 locationNCT07481669
Recruiting
Phase 2

Immunoprevention for High-risk Lung Lesions

High-risk Lung Nodules
Robert Samstein59 enrolled1 locationNCT07284485
Recruiting
Phase 3

Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

High-risk Melanoma
Uppsala University1,792 enrolled26 locationsNCT06488482
Recruiting
Phase 3

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 4

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)Human Papillomavirus (HPV) InfectionsHigh-risk HPV+1 more
Miquel Angel Pavon Ribas69 enrolled1 locationNCT05334706
Recruiting
Not Applicable

Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study

Pulmonary EmbolismPulmonary Embolism AcuteNon-severe Pulmonary Embolism+5 more
University Hospital, Rouen180 enrolled1 locationNCT06166329
Recruiting

Prevent Cancer- Greenville

CancerHigh-Risk Cancer
Prisma Health-Upstate1,000 enrolled1 locationNCT04947098
Recruiting
Early Phase 1

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

High-risk Prostate Cancer
Edwin Posadas, MD20 enrolled1 locationNCT06888102
Recruiting
Not Applicable

Use of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures

High-risk PCICoronary Artery Disease Risk High
Amsterdam UMC, location VUmc98 enrolled8 locationsNCT07380217
Recruiting
Phase 2

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD32 enrolled6 locationsNCT05498272
Recruiting
Phase 2

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Hormone Receptor-Positive Breast CancerHigh-risk Breast Cancer
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Not Applicable

Liquid Biopsy-Based Pre-Screening to Streamline LDCT Lung Cancer Screening in High-Risk Individuals

Lung CancerLung NeoplasmsCancer Screening+2 more
National University Hospital, Singapore140 enrolled1 locationNCT07358715